Halozyme Therapeutics, Inc. Overview
Pro stress-test →Halozyme Therapeutics develops the ENHANZE drug delivery system, which makes it easier for drugs to be delivered subcutaneously, or to the innermost layer of the skin. The proprietary enzyme rHuPH20 facilitates rapid subcutaneous delivery of injected drugs with reduced treatment burden. The company generates revenue primarily through royalties on partner-developed therapeutics, achieving exceptional growth momentum with royalty revenue expected to exceed 50% year-over-year growth in 2025.
Strategic Profile
Pro stress-test →Halozyme's acquisitions of Elektrofi and Surf Bio extend its IP runway beyond the 2027 ENHANZE patent expiration, supporting long-term revenue sustainability. The three most successful ENHANZE-enabled products include Johnson & Johnson's Darzalex Faspro for multiple myeloma, argenx's VYVGART Hytrulo for myasthenia gravis, and Roche's Phesgo for HER2-positive breast cancer. The Surf Bio acquisition adds a hyperconcentration technology achieving approximately 500 mg/mL concentrations—3-4x higher than typical formulations.
Competitive Landscape
Pro stress-test →Competitors include Heron Therapeutics, Alteogen, Immune-Onc Therapeutics, Crinetics Pharmaceuticals, and Ayala Pharmaceuticals among 22 total competitors. Halozyme's asset-light royalty model and established partnerships with major pharma differentiate it from drug development-focused biotech peers. The company faces patent expiration risks for ENHANZE beyond 2027, but recent acquisitions diversify its technology platform.
Industry Context
Halozyme Therapeutics, Inc. operates in Biopharmaceuticals / Drug Delivery Technology Licensing.
Key facts
Founded: 1998 · Headquarters: Del Mar, US · Employees: ~380 · Revenue: $1.39B (FY 2025 preliminary) · Market cap: $7.7B